Peter Olson

发表

Targeting Krasg12c‐mutant cancer with a mutation‐specific inhibitor

M. Bergo, J. Christensen, P. Olson, 2020, Journal of internal medicine.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

G. Vigers, J. Gaudino, Jennifer N. Otten, 2020, Journal of medicinal chemistry.

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.

V. Velcheti, Zhaoyuan Fang, Minglei Shi, 2024, Cancer cell.

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

V. Velcheti, Fei Li, A. Aguirre, 2023, bioRxiv.

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers

K. Wennerberg, C. Der, K. Lim, 2024, Science.

TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors.

C. Der, Andrew M. Waters, Jill Hallin, 2023, Cancer research.